Serum Institute gets DCGI nod to resume clinical trial of Oxford COVID-19 vaccine
Drugs Controller General of India (DCGI) V.G. Somani has gave permission to Serum Institute of India (SII) to resume clinical trial of the Oxford COV
Full Article
Serum Institute gets DCGI nod to resume clinical trial of Oxford COVID-19 vaccine
Hindu
0 shares
1 views
You might like
Related news coverage
Mumbai: Clinical trial of COVID-19 vaccine begins at KEM, Nair hospitals
Mid-Day
Three candidates in the age group of 25 to 45 were given the first trial dose of COVID-19 vaccine, developed by the Oxford..
-
Can Centre procure Rs 80,000 crore to buy, distribute COVID-19 vaccine across India? SII CEO Adar Poonawalla
DNA
-
Can Centre procure Rs 80,000 crore to buy, distribute COVID-19 vaccine across India? SII CEO Adar Poonawalla asks
DNA
-
Mumbai: KEM hospital gets gets nod for COVID-19 vaccine trials
Mid-Day
-
Phase 3 human clinical trial of Oxford vaccine begins in Pune
IndiaTimes
Advertisement
More coverage
Phase 3 trial of Oxford vaccine begins in Pune
IndiaTimes
The phase-III human clinical trial of the Covid-19 vaccine being developed by Oxford University, and manufactured by the Serum..
-
Phase 3 trial of Oxford vaccine from next week
IndiaTimes
-
COVID-19 vaccination to be available by 'start of next year': Harsh Vardhan
Mid-Day
-
Serum Institute of India gets DCGI nod to resume clinical trial of Oxford COVID-19 vaccine
Mid-Day
-
Serum Institute of India gets DCGI permission to restart phase 2, 3 trials of coronavirus COVID-19 vaccine
Zee News